Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE4
Total Enrollment
21442 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-06-30
Study Completion Date
2023-06-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to determine whether taking daily, dietary supplements of cocoa extract (containing cocoa flavanols and theobromine from the cocoa bean) and/or a standard multivitamin reduces the risk of developing cardiovascular disease (including heart attack, stroke, coronary revascularization, unstable angina or acute coronary syndrome (ACS) requiring hospitalization, carotid artery surgery, and peripheral artery surgery or angioplasty, and cardiovascular mortality) and cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Cocoa Supplementation and Aerobic Exercise on Pressure Parameters
NCT04732754
Sedentary Behavior
UNKNOWN
NA
Study for the Liquid Chromatography-mass Spectrometry (LC-MS/MS) Assessment of Oxidative DNA Damage in Relation to Antioxidant Usage
NCT01038024
Cancer
COMPLETED
NA
Effects of Supplementation in Healthy Russian Population
NCT02224092
Heart Health Markers
General Nutritional Status
COMPLETED
NA
Racial and Aging Effects of Acute Antioxidant Supplementation
NCT02157207
Healthy
COMPLETED
NA
Effect of Cocoa Supplementation in Training Athletes Microbiota and Metabolome
NCT04444388
Healthy Athletes
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The COcoa Supplement and Multivitamin Outcomes Study (COSMOS) is a randomized clinical trial of cocoa extract supplement (containing a total of 600 mg/d cocoa flavanols, including 80 mg. (-)-epicatechins), and a standard multivitamin supplement to reduce the risk of cardiovascular disease and cancer among women aged 65 years and older and men aged 60 years and older.
After the COSMOS trial began, an advanced method to analyze cocoa flavanols was accredited by AOAC International as a First Action Official Method of Analysis (https://doi.org/10.1093/jaoacint/qsaa132). This updated method relies on a reference material (RM8403) recently standardized and made commercially available by the U.S. National Institute of Standards and Technology. While the actual cocoa flavanol content of the COSMOS intervention remained unchanged throughout the trial, the application of this new analytical method led to expected changes in how the total cocoa flavanol content is now reported. Applying AOAC 2020.05/RM8403 to the COSMOS intervention, the total cocoa flavanol content of the COSMOS intervention is now 500 mg/day. Reporting of (-)-epicatechin content remained unaffected. Going forward, we will therefore apply AOAC 2020.05/RM8403 and report that the COSMOS intervention tested 500 mg/day of cocoa flavanols, including 80 mg of (-)-epicatechin.
Participants in COSMOS were recruited from among Women's Health Initiative (WHI) Extension Study cohort members; non-randomized respondents to mailings for the VITamin D and OmegA-3 TriaL (VITAL); respondents to nationwide invitational mailings to age-eligible adults; and volunteers who learned about the trial through the media or through ResearchMatch.org, an electronic recruitment website.
Several small randomized trials have demonstrated benefits for cocoa flavanols on intermediate outcomes, including blood pressure, lipids, insulin sensitivity, and flow-mediated vasodilation. For multivitamins, a prior large-scale randomized trial in middle-aged and older men showed a significant reduction in cancer, but comparable trial data in women are lacking. For both interventions, a large-scale clinical trial such as COSMOS could have major clinical and public health implications.
Eligible participants have been assigned by chance (like a coin toss) to one of four groups: (1) daily cocoa extract and multivitamin; (2) daily cocoa extract and multivitamin placebo; (3) daily cocoa extract placebo and multivitamin; or (4) daily cocoa extract placebo and multivitamin placebo. Participants have an equal chance of being assigned to any of these four groups and a 3 out of 4 chance of receiving at least one active agent.
Participants in all groups take three pills each day: two capsules that contain either cocoa extract or cocoa extract placebo, and one tablet that contains either multivitamin or multivitamin placebo. Participants receive their study pills in convenient calendar packs via U.S. mail.
Participants are asked to complete mailed questionnaires each year. The questionnaires ask about health; lifestyle habits, such as diet, physical activity, and smoking; use of medications and dietary supplements; family history of illness and new medical diagnoses. Occasionally, participants may receive a phone call from study staff to collect information or clarify responses on the questionnaires.
The expected rates for our original primary composite cardiovascular disease (CVD) endpoint were based on the projected age and sex distribution of the trial cohort and CVD event rates from our previously conducted trials. However, we determined that the observed rates of CVD endpoints among COSMOS participants were lower than expected due to a younger population of women, increasing use of statins and other pharmacotherapies as seen in other recently published clinical trials, and the impact of COVID-19 on fewer reports of CVD diagnoses, hospitalizations, and procedures. As a result, the COSMOS Data and Safety Monitoring Board (DSMB) approved a proposal to add three new outcomes to our primary composite CVD endpoint: (1) unstable angina or acute coronary syndrome requiring hospitalization, (2) carotid artery surgery, and (3) peripheral artery surgery or angioplasty. These additional CVD outcomes are consistent with the atherosclerotic mechanisms underlying the postulated effects for the randomized interventions. COSMOS participants have already provided self-reports of these diagnoses since the start of the COSMOS trial that will be adjudicated via medical records. The original primary composite CVD endpoint will still be evaluated as a secondary outcome.
At baseline, approximately 7,000 COSMOS participants provided optional blood and urine samples, which will be used to determine whether the study agents significantly change biomarkers and other risk factors related to cardiovascular disease and cancer. Selected participants either have specimens collected through mailed specimen collection kits that are returned by the participant, or have blood, urine, blood pressure, and anthropometric measurements collected by technicians from Examination Management Services, Inc. (EMSI), a national clinical services provider. A subgroup of those who provide baseline specimens and measurements are asked to provide follow-up samples and measurements.
At baseline and year 2 of the trial, approximately 600 participants living within driving distance of Boston, Massachusetts provide additional measurements from in-clinic study visits at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. These visits include cognitive function assessments, anthropometrics, physical function assessments, blood pressure and other measurements. The trial will assess whether the study agents significantly affect changes in these variables over time.
Primary Hypotheses:
1. A cocoa extract supplement will reduce the risk of major cardiovascular events, defined as a composite endpoint of myocardial infarction, stroke, cardiovascular mortality, coronary revascularization, unstable angina or ACS requiring hospitalization, carotid artery surgery, and peripheral artery surgery or angioplasty;
2. A daily multivitamin will reduce the risk of invasive cancer (excluding non-melanoma skin cancer).
Secondary Hypotheses:
1. Cocoa extract will reduce the risk of a composite endpoint of MI, stroke, cardiovascular mortality, and coronary revascularization;
2. Cocoa extract will reduce the risk of invasive cancer (excluding non-melanoma skin cancer);
3. A daily multivitamin will reduce the risk of major cardiovascular events;
4. Cocoa extract and/or a daily multivitamin will reduce the combined endpoint of major cardiovascular events plus all-cause mortality;
5. Cocoa extract and/or a daily multivitamin will reduce the risk of individual cardiovascular events, including myocardial infarction, stroke, cardiovascular mortality, coronary revascularization, unstable angina or ACS requiring hospitalization, carotid artery surgery, and peripheral artery surgery or angioplasty, and total mortality; plus site-specific cancers, including breast, colorectal, and lung cancer;
6. A daily multivitamin will reduce the risk of cancer among women and men with a history of cancer at baseline;
7. In a subset of equal numbers of female and male COSMOS respondents who provide baseline bloods and/or urine samples, cocoa extract and/or a daily multivitamin will significantly change blood and/or urinary levels of flavonoids or their metabolites from baseline to 1, 2, or 3 years of follow-up.
Tertiary Aim:
To assess whether the cocoa extract and/or a daily multivitamin exhibit synergistic effects on risk of major cardiovascular events or cancer, and if the effects vary by nutritional status or medication use.
Aims of Clinical and Translational Science Center (CTSC) Component:
To test whether the cocoa extract and/or a daily multivitamin has beneficial effects on:
1. Systolic and diastolic blood pressure;
2. Pulse wave velocity (PWV) and central blood pressure indices as measured by pulse wave analysis;
3. Cognitive function and memory;
4. Physical performance as assessed by balance tests, grip strength, timed chair stands, and walking speed,
5. Bone loss in the spine, hip and total body as assessed by bone-mineral density (BMD) and changes in body composition as assessed by dual x-ray absorpiometry (DXA);
After the COSMOS trial began, an advanced method to analyze cocoa flavanols was accredited by AOAC International as a First Action Official Method of Analysis (https://doi.org/10.1093/jaoacint/qsaa132). This updated method relies on a reference material (RM8403) recently standardized and made commercially available by the U.S. National Institute of Standards and Technology. While the actual cocoa flavanol content of the COSMOS intervention remained unchanged throughout the trial, the application of this new analytical method led to expected changes in how the total cocoa flavanol content is now reported. Applying AOAC 2020.05/RM8403 to the COSMOS intervention, the total cocoa flavanol content of the COSMOS intervention is now 500 mg/day. Reporting of (-)-epicatechin content remained unaffected. Going forward, we will therefore apply AOAC 2020.05/RM8403 and report that the COSMOS intervention tested 500 mg/day of cocoa flavanols, including 80 mg of (-)-epicatechin.
Participants in COSMOS were recruited from among Women's Health Initiative (WHI) Extension Study cohort members; non-randomized respondents to mailings for the VITamin D and OmegA-3 TriaL (VITAL); respondents to nationwide invitational mailings to age-eligible adults; and volunteers who learned about the trial through the media or through ResearchMatch.org, an electronic recruitment website.
Several small randomized trials have demonstrated benefits for cocoa flavanols on intermediate outcomes, including blood pressure, lipids, insulin sensitivity, and flow-mediated vasodilation. For multivitamins, a prior large-scale randomized trial in middle-aged and older men showed a significant reduction in cancer, but comparable trial data in women are lacking. For both interventions, a large-scale clinical trial such as COSMOS could have major clinical and public health implications.
Eligible participants have been assigned by chance (like a coin toss) to one of four groups: (1) daily cocoa extract and multivitamin; (2) daily cocoa extract and multivitamin placebo; (3) daily cocoa extract placebo and multivitamin; or (4) daily cocoa extract placebo and multivitamin placebo. Participants have an equal chance of being assigned to any of these four groups and a 3 out of 4 chance of receiving at least one active agent.
Participants in all groups take three pills each day: two capsules that contain either cocoa extract or cocoa extract placebo, and one tablet that contains either multivitamin or multivitamin placebo. Participants receive their study pills in convenient calendar packs via U.S. mail.
Participants are asked to complete mailed questionnaires each year. The questionnaires ask about health; lifestyle habits, such as diet, physical activity, and smoking; use of medications and dietary supplements; family history of illness and new medical diagnoses. Occasionally, participants may receive a phone call from study staff to collect information or clarify responses on the questionnaires.
The expected rates for our original primary composite cardiovascular disease (CVD) endpoint were based on the projected age and sex distribution of the trial cohort and CVD event rates from our previously conducted trials. However, we determined that the observed rates of CVD endpoints among COSMOS participants were lower than expected due to a younger population of women, increasing use of statins and other pharmacotherapies as seen in other recently published clinical trials, and the impact of COVID-19 on fewer reports of CVD diagnoses, hospitalizations, and procedures. As a result, the COSMOS Data and Safety Monitoring Board (DSMB) approved a proposal to add three new outcomes to our primary composite CVD endpoint: (1) unstable angina or acute coronary syndrome requiring hospitalization, (2) carotid artery surgery, and (3) peripheral artery surgery or angioplasty. These additional CVD outcomes are consistent with the atherosclerotic mechanisms underlying the postulated effects for the randomized interventions. COSMOS participants have already provided self-reports of these diagnoses since the start of the COSMOS trial that will be adjudicated via medical records. The original primary composite CVD endpoint will still be evaluated as a secondary outcome.
At baseline, approximately 7,000 COSMOS participants provided optional blood and urine samples, which will be used to determine whether the study agents significantly change biomarkers and other risk factors related to cardiovascular disease and cancer. Selected participants either have specimens collected through mailed specimen collection kits that are returned by the participant, or have blood, urine, blood pressure, and anthropometric measurements collected by technicians from Examination Management Services, Inc. (EMSI), a national clinical services provider. A subgroup of those who provide baseline specimens and measurements are asked to provide follow-up samples and measurements.
At baseline and year 2 of the trial, approximately 600 participants living within driving distance of Boston, Massachusetts provide additional measurements from in-clinic study visits at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. These visits include cognitive function assessments, anthropometrics, physical function assessments, blood pressure and other measurements. The trial will assess whether the study agents significantly affect changes in these variables over time.
Primary Hypotheses:
1. A cocoa extract supplement will reduce the risk of major cardiovascular events, defined as a composite endpoint of myocardial infarction, stroke, cardiovascular mortality, coronary revascularization, unstable angina or ACS requiring hospitalization, carotid artery surgery, and peripheral artery surgery or angioplasty;
2. A daily multivitamin will reduce the risk of invasive cancer (excluding non-melanoma skin cancer).
Secondary Hypotheses:
1. Cocoa extract will reduce the risk of a composite endpoint of MI, stroke, cardiovascular mortality, and coronary revascularization;
2. Cocoa extract will reduce the risk of invasive cancer (excluding non-melanoma skin cancer);
3. A daily multivitamin will reduce the risk of major cardiovascular events;
4. Cocoa extract and/or a daily multivitamin will reduce the combined endpoint of major cardiovascular events plus all-cause mortality;
5. Cocoa extract and/or a daily multivitamin will reduce the risk of individual cardiovascular events, including myocardial infarction, stroke, cardiovascular mortality, coronary revascularization, unstable angina or ACS requiring hospitalization, carotid artery surgery, and peripheral artery surgery or angioplasty, and total mortality; plus site-specific cancers, including breast, colorectal, and lung cancer;
6. A daily multivitamin will reduce the risk of cancer among women and men with a history of cancer at baseline;
7. In a subset of equal numbers of female and male COSMOS respondents who provide baseline bloods and/or urine samples, cocoa extract and/or a daily multivitamin will significantly change blood and/or urinary levels of flavonoids or their metabolites from baseline to 1, 2, or 3 years of follow-up.
Tertiary Aim:
To assess whether the cocoa extract and/or a daily multivitamin exhibit synergistic effects on risk of major cardiovascular events or cancer, and if the effects vary by nutritional status or medication use.
Aims of Clinical and Translational Science Center (CTSC) Component:
To test whether the cocoa extract and/or a daily multivitamin has beneficial effects on:
1. Systolic and diastolic blood pressure;
2. Pulse wave velocity (PWV) and central blood pressure indices as measured by pulse wave analysis;
3. Cognitive function and memory;
4. Physical performance as assessed by balance tests, grip strength, timed chair stands, and walking speed,
5. Bone loss in the spine, hip and total body as assessed by bone-mineral density (BMD) and changes in body composition as assessed by dual x-ray absorpiometry (DXA);
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cardiovascular Disease
Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
FACTORIAL
Primary Study Purpose
PREVENTION
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cocoa extract + multivitamin
Group Type
ACTIVE_COMPARATOR
Cocoa extract
Intervention Type
DIETARY_SUPPLEMENT
2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
Multivitamin
Intervention Type
DIETARY_SUPPLEMENT
Multivitamin
Cocoa extract + multivitamin placebo
Group Type
ACTIVE_COMPARATOR
Cocoa extract
Intervention Type
DIETARY_SUPPLEMENT
2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
Multivitamin placebo
Intervention Type
DIETARY_SUPPLEMENT
Multivitamin placebo
Cocoa extract placebo + multivitamin
Group Type
ACTIVE_COMPARATOR
Multivitamin
Intervention Type
DIETARY_SUPPLEMENT
Multivitamin
Cocoa extract placebo
Intervention Type
DIETARY_SUPPLEMENT
Cocoa extract placebo
Cocoa extract placebo + multivitamin placebo
Group Type
PLACEBO_COMPARATOR
Cocoa extract placebo
Intervention Type
DIETARY_SUPPLEMENT
Cocoa extract placebo
Multivitamin placebo
Intervention Type
DIETARY_SUPPLEMENT
Multivitamin placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cocoa extract
2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
Intervention Type
DIETARY_SUPPLEMENT
Multivitamin
Multivitamin
Intervention Type
DIETARY_SUPPLEMENT
Cocoa extract placebo
Cocoa extract placebo
Intervention Type
DIETARY_SUPPLEMENT
Multivitamin placebo
Multivitamin placebo
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Women ≥ 65 years of age participating in the Women's Health Initiative (WHI) Extension Study.
2. Men ≥ 60 years of age and women age ≥ 65 years of age who were contacted for but not randomized into the VITAL trial.
3. Other women ≥ 65 years of age and men aged ≥ 60 years of age who responded to targeted mass mailings and volunteers who learned about the trial through the media or through ResearchMatch.org, an electronic recruitment website.
4. Willing to participate, as evidenced by providing informed consent and completing all required baseline forms.
2. Men ≥ 60 years of age and women age ≥ 65 years of age who were contacted for but not randomized into the VITAL trial.
3. Other women ≥ 65 years of age and men aged ≥ 60 years of age who responded to targeted mass mailings and volunteers who learned about the trial through the media or through ResearchMatch.org, an electronic recruitment website.
4. Willing to participate, as evidenced by providing informed consent and completing all required baseline forms.
Exclusion Criteria
1. History of myocardial infarction or stroke.
2. Diagnosed with invasive cancer other than non-melanoma skin cancer in the last 2 years prior to enrollment.
3. Any serious illness that would preclude participation and/or completion of the trial, including the diagnosis of kidney failure and current dialysis treatment.
4. Taking cocoa extract or multivitamin supplements and not willing to forego use during the trial.
5. Taking total supplemental vitamin D \> 1,000 IU/day and not willing to forego use during the trial.
6. Taking total supplemental calcium \> 1,200 mg/day and not willing to forego use during the trial.
7. Extreme sensitivity to caffeine.
8. Consume \< 75% of the expected number of both types of supplements during the run-in phase.
9. Unable to communicate in English due to language barrier or mental incapacity.
2. Diagnosed with invasive cancer other than non-melanoma skin cancer in the last 2 years prior to enrollment.
3. Any serious illness that would preclude participation and/or completion of the trial, including the diagnosis of kidney failure and current dialysis treatment.
4. Taking cocoa extract or multivitamin supplements and not willing to forego use during the trial.
5. Taking total supplemental vitamin D \> 1,000 IU/day and not willing to forego use during the trial.
6. Taking total supplemental calcium \> 1,200 mg/day and not willing to forego use during the trial.
7. Extreme sensitivity to caffeine.
8. Consume \< 75% of the expected number of both types of supplements during the run-in phase.
9. Unable to communicate in English due to language barrier or mental incapacity.
Minimum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fred Hutchinson Cancer Center
OTHER
Sponsor Role
collaborator
Mars, Inc.
INDUSTRY
Sponsor Role
collaborator
Pfizer
INDUSTRY
Sponsor Role
collaborator
Brigham and Women's Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
JoAnn E. Manson, MD
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
JoAnn E. Manson, MD
Role: PRINCIPAL_INVESTIGATOR
Brigham and Women's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brigham and Women's Hospital
Boston, Massachusetts, United States
Site Status
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Vyas CM, Manson JE, Sesso HD, Cook NR, Rist PM, Weinberg A, Moorthy MV, Baker LD, Espeland MA, Yeung LK, Brickman AM, Okereke OI. Effect of multivitamin-mineral supplementation versus placebo on cognitive function: results from the clinic subcohort of the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial and meta-analysis of 3 cognitive studies within COSMOS. Am J Clin Nutr. 2024 Mar;119(3):692-701. doi: 10.1016/j.ajcnut.2023.12.011. Epub 2024 Jan 18.
Reference Type
DERIVED
Vyas CM, Manson JE, Sesso HD, Rist PM, Weinberg A, Kim E, Moorthy MV, Cook NR, Okereke OI. Effect of cocoa extract supplementation on cognitive function: results from the clinic subcohort of the COSMOS trial. Am J Clin Nutr. 2024 Jan;119(1):39-48. doi: 10.1016/j.ajcnut.2023.10.031. Epub 2023 Dec 7.
Reference Type
DERIVED
Sesso HD, Rist PM, Aragaki AK, Rautiainen S, Johnson LG, Friedenberg G, Copeland T, Clar A, Mora S, Moorthy MV, Sarkissian A, Wactawski-Wende J, Tinker LF, Carrick WR, Anderson GL, Manson JE; COSMOS Research Group. Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. Am J Clin Nutr. 2022 Jun 7;115(6):1501-1510. doi: 10.1093/ajcn/nqac056.
Reference Type
DERIVED
Sesso HD, Manson JE, Aragaki AK, Rist PM, Johnson LG, Friedenberg G, Copeland T, Clar A, Mora S, Moorthy MV, Sarkissian A, Carrick WR, Anderson GL; COSMOS Research Group. Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. Am J Clin Nutr. 2022 Jun 7;115(6):1490-1500. doi: 10.1093/ajcn/nqac055.
Reference Type
DERIVED
Rist PM, Sesso HD, Johnson LG, Aragaki AK, Wang L, Rautiainen S, Hazra A, Tobias DK, LeBoff MS, Schroeter H, Friedenberg G, Copeland T, Clar A, Tinker LF, Hunt RP, Bassuk SS, Sarkissian A, Smith DC, Pereira E, Carrick WR, Wion ES, Schoenberg J, Anderson GL, Manson JE; COSMOS Research Group. Design and baseline characteristics of participants in the COcoa Supplement and Multivitamin Outcomes Study (COSMOS). Contemp Clin Trials. 2022 May;116:106728. doi: 10.1016/j.cct.2022.106728. Epub 2022 Mar 12.
Reference Type
DERIVED
Baker LD, Rapp SR, Shumaker SA, Manson JE, Sesso HD, Gaussoin SA, Harris D, Caudle B, Pleasants D, Espeland MA; COSMOS-Mind Research Group. Design and baseline characteristics of the cocoa supplement and multivitamin outcomes study for the Mind: COSMOS-Mind. Contemp Clin Trials. 2019 Aug;83:57-63. doi: 10.1016/j.cct.2019.06.019. Epub 2019 Jul 2.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
https://www.cosmostrial.org
COSMOS Trial website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014P002768
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effects of Coenzyme Q10 Supplement on Cardiovascular Risk Factors in Subjects at High Risk of Metabolic Syndrome
NCT06506630
RECRUITING
NA
Effects of Dietary Antioxidants on Cardiovascular Risk Factors
NCT00756405
COMPLETED
NA
Chocolate and Physical Exercise to Reduce Malnutrition in Pre-dementia Aged People
NCT05343611
UNKNOWN
NA
Procyanidin B2 Enriched Cocoa Effects on Mitochondrial Biogenesis
NCT04301583
COMPLETED
NA
To Evaluate the Efficacy of a Nutraceutical in Reducing Cardiovascular Risk in Healthy Subjects
NCT04506749
COMPLETED
NA
The Effects of a Novel Mitochondrial Substrate Supplement on Exercise Performance and Cognitive Function
NCT06374641
RECRUITING
NA
Impact Of Antioxidant Micronutrients On Intensive Care Unit (ICU) Outcome
NCT00515736
TERMINATED
PHASE3
Treating Oxidative Stress and the Metabolic Pathology of Autism
NCT00572741
COMPLETED
NA
Phase III Trial of Coenzyme Q10 in Mitochondrial Disease
NCT00432744
COMPLETED
PHASE3
Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations
NCT06640465
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
Effects of a Recovery Supplement on Body Composition, Performance, Muscular Properties, and Wellbeing
NCT05769101
COMPLETED
NA
The Effects of the Dietary Supplement CardioFlex Q10 on Reducing Cardiovascular Disease Risk Factors in Adults
NCT03826914
COMPLETED
NA
Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers
NCT04808622
COMPLETED
PHASE1
Coenzyme Q-10 and Pulmonary Arterial Hypertension
NCT01148836
COMPLETED
NA
Antioxidant Therapy for COVID-19 Study
NCT04466657
WITHDRAWN
NA
Effect of Oral Intake of Bacopa Monneiri on Vascular Oxidative Stress
NCT06355167
COMPLETED
NA
Effects of Lutein Supplementation on Oxidative Stress and Inflammation in Healthy Nonsmokers
NCT01056094
UNKNOWN
PHASE1/PHASE2
Effects of a Pre-Workout on Performance, Perceptual Responses, Energy Feelings and Muscular Properties, After a Training Microcycle in Adults.
NCT04147741
COMPLETED
NA
Effect of Endurance Training-Induced Coenzyme Q10 (CoQ10) Supplementation on Myokine, Exerkine Secretion and Cognitive Functions in Long-Distance Runners
NCT06619249
RECRUITING
PHASE4
Effects of Maca Supplementation on Badminton-specific Exercise Performance
NCT07082985
COMPLETED
NA
Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.
NCT04869579
UNKNOWN
PHASE2
Investigation of Dietary Supplement Liquid Shot Products on Mental Energy, Cognition (Acuity),and Mood
NCT06384586
COMPLETED
NA
Taurine Supplementation and Triathletes
NCT03155919
COMPLETED
NA
Oxidative Stress and Nutritional Supplementation Intervention Study
NCT01234506
COMPLETED
PHASE2